Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug
Executive Summary
Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.
You may also be interested in...
Distributing Health, Beauty Products To Retailers, Hims & Hers Seeds Field For OTC ED Drug Sales
With ED ingredients frequently mentioned as OTC switch candidates in US, Hims & Hers Health is another latest direct-to-consumer marketer establishing network of retailers to offer potential OTC ED drug as it makes its consumer health and personal care products available in stores.
Petros Includes Nitrate Patients In OTC ED Drug Self-Selection Studies
Firms also notes in its announcement that FDA typically requires actual use trials for switch NDAs in addition to label comprehension studies, which it has conducted, and self-selection studies.
German Rx-To-OTC Switch Committee To Consider Sildenafil Reclassification
Rx-to-OTC switches of sildenafil and xylometazoline and ipratropium bromide combinations are on the cards for January's meeting of the German Expert Committee for Prescription.